Eltrogis 50 Tablet

Description of Eltrogis 50 (Eltrombopag 50 mg) Tablet

Eltrombopag, which is a part of Eltrogis 50 Tablet, is a thrombopoietin receptor agonist that is used to stimulate platelet production in patients with certain haematological issues. It is mostly recommended to treat disorders that are mainly marked by thrombocytopenia as a result of disrupted platelet genesis. In physiological conditions, thrombopoietin binds to bone marrow stimulating it to produce platelets; Eltrombopag mimics this process by binding to megakaryocyte thrombopoietin receptors, thus stimulating platelet production and reducing the risk of haemorrhage. It is an oral agent that is used when other treatment solutions have not yielded enough results.

Indications of Eltrogis 50 (Eltrombopag 50 mg) Tablet

Eltrogis 50 mg pill is to be taken in combination with other blood clotting medications and in patients having severe blood loss. Eltrombopag is used in treatment of chronic immune thrombocytopenia (ITP), thrombocytopenia in chronic hepatitis C as well as severe aplastic anaemia. It is primarily applied to the patients that have shown a limited response to the preliminary regimens involving the administration of corticosteroids or immunoglobulins.

Mechanism of action of Eltrogis 50 (Eltrombopag 50 mg) Tablet

Eltrombopag is applied in the therapy of chronic immune thrombocytopenia (ITP), thrombocytopenia in chronic hepatitis C and severe aplastic anaemia. It is primarily administered on individuals who have been found to have low response to the initial regimens involving the administration of corticosteroids or immunoglobulins. In contrast to naturally generated thrombopoietin, Eltrombopag attaches to a different receptor site, thus increasing platelet formation with no Agonistic effect on natural TPO. This causes platelet counts to increase and hence the bleeding complications are reduced.

How to consume Eltrogis 50 (Eltrombopag 50 mg) Tablet

Eltrombopag is provided in oral tablet preparation. The suggested dose regimen assumes taking it on an empty stomach at least one hour before or at least two hours after meals. The prescribing doctor individualises the dosage depending on the platelet count and response. Periodic measurement of platelet count is an essential factor in order to adjust dosage and avoid the over-thrombocytosis.

Side Effects of Eltrogis 50 (Eltrombopag 50 mg) Tablet

1. Common side effects

• Headache
• Nausea
• Fatigue
• Diarrhea
• Increased liver enzymes

2. Serious side effects

• Hepatotoxicity
• Thromboembolic events
• Bone marrow fibrosis
• Severe thrombocytosis

3. Rare side effects

• Cataracts
• Severe hypersensitivity reactions

Safety Advice for Eltrogis 50 (Eltrombopag 50 mg) Tablet

Eltrombopag is provided in oral tablet preparation. The suggested dose regimen assumes taking it on an empty stomach at least one hour before or at least two hours after meals.

Breastfeeding: The drug should not be breastfed due to the possibility of it being transferred to breast milk

Pregnancy: The use of pregnancy is only justified in cases where there is an evident need because foetal risks can never be minimised.

Alcohol: Alcohol intake ought also to be kept down as it has the potential of enhancing hepatotoxicity.

Liver: In case of hepatic impairment care and constant observation should be applied.

Lungs: Patients should report about the shortness of breath or the chest pains.

Kidney: Renal impairment will require a careful dosing.

Driving: One should not be in the condition of dizziness or fatigue while driving.

Interaction of Eltrogis 50 (Eltrombopag 50 mg) Tablet

• Drug–Drug Interaction

Antacids × Eltrombopag
May reduce absorption due to chelation with polyvalent cations.

Calcium supplements × Eltrombopag
May decrease drug effectiveness by binding to the drug in the gut.

Rifampicin × Eltrombopag
May reduce plasma levels and decrease efficacy.

Warfarin × Eltrombopag
May increase risk of thrombotic complications.

Statins × Eltrombopag
May increase statin concentration and risk of toxicity.

• Drug–Food Interaction

Eltrombopag (Eltrogis 50mg) tablets must not be administered with high-calcium, iron, or magnesium foodstuffs because it reduces the absorption of Eltrombopag and should not be administered around meals.

• Drug–Disease Interaction

Liver disease:
It is possible that patients with liver disease will have higher enzyme level and worsening of hepatic functions; frequent monitoring is needed.

Thromboembolic disorders:
With thromboembolic disorders, high platelet count can lead to more clots in people who are prone to clots.

Bone marrow disorders:
Long-term use may cause bone marrow fibrosis in some patients.

Cataract risk:
Long term treatment can make the cataracts more likely to occur.

Contraindication of Eltrogis 50 (Eltrombopag 50 mg) Tablet

Eltrombopag should not be used in patients that had hypersensitivity to the drug or the drug components in addition to severe liver disease that is to be used cautiously.

Dosage of Eltrogis 50 (Eltrombopag 50 mg) Tablet

The dosage must be changed according to the platelet count and response of the patien. It is periodically adjusted in order to protect safe platelet levels and avoid complications.

Storage of Eltrogis 50 (Eltrombopag 50 mg) Tablet

Store at room temperature, but kept out of moisture and heat. Keep out of reach of children.

Missed Dose of Eltrogis 50 (Eltrombopag 50 mg) Tablet

In case of a missed dose, this should be omitted and the next dose of the drug should be taken at the correct time.

Other General Information of Eltrogis 50 (Eltrombopag 50 mg) Tablet

The dietary instructions should be adhered by the patients so that they can adequately absorb the drugs. Platelet count and liver functioning should be observed, which should be done regularly. There are symptoms that are to be reported immediately like abnormal bleeding, yellowish skin or severe headache.

FAQs of Eltrogis 50 (Eltrombopag 50 mg) Tablet

1. How does Eltrombopag increase platelets?
   It stimulates thrombopoietin receptors to increase platelet production in bone marrow.
2. Can it cause blood clots?
   Yes, excessive platelet increase may raise thrombotic risk.
3. Why avoid calcium-rich food?
   It reduces drug absorption and effectiveness.
4. Is monitoring necessary?
   Yes, platelet and liver function must be checked regularly.
5. Can it be used long-term?
   Yes, but under strict medical supervision.

Fact Box of Eltrogis 50 (Eltrombopag 50 mg) Tablet

References

• FDA Prescribing Information – Eltrombopag (Promacta)
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022291s030lbl.pdf
• European Medicines Agency (EMA) – Revolade Product Information
  https://www.ema.europa.eu/en/documents/product-information/revolade-epar-product-information_en.pdf
• DrugBank – Eltrombopag Profile
  https://go.drugbank.com/drugs/DB06210
• National Cancer Institute (NCI) – Eltrombopag
  https://www.cancer.gov/about-cancer/treatment/drugs/eltrombopag